Direction
Buy
Sell
Types
LMT Order
Price
QTY
Amount
--
ADCT ADC Therapeutics
4.560-0.070-1.51%
Close
02/06 16:00 ET
4.5600.0000.00%
Post Mkt Price 02/06 16:00 ET
High
4.740
Open
4.600
Turnover
1.19M
Low
4.500
Pre Close
4.630
Volume
259.49K
Post-Market
5D
1D
1W
1M
1Q
1Y
Price Forecast
News
Comment
ADC Therapeutics Announces Pricing of Underwritten Offering by a Selling Shareholder
ADC Therapeutics SA ("ADCT" or the "Company") (NYSE:ADCT), a commercial-stage biotechnology company helping to improve the lives of those affected by cancer with its next-generation, targeted antibody drug conjugates,
ADC Therapeutics Expects That Product Revenues, Net, Will Be About $19.8M For Three Months Ended Dec. 31, 2022; Expects Cash And Cash Equivalents Will Be About $326.4M As Of Dec. 31, 2022
ADC Therapeutics Expects That Product Revenues, Net, Will Be About $19.8M For Three Months Ended Dec. 31, 2022; Expects Cash And Cash Equivalents Will Be About $326.4M As Of Dec. 31, 2022
ADC Therapeutics to Participate in February Investor Conferences
ADC Therapeutics SA (NYSE:ADCT) announced today that Ameet Mallik, Chief Executive Officer, will participate in two investor conferences in February. Details of the events are as follows: Guggenheim Healthcare Talks
Morgan Stanley Lowers ADC Therapeutics (NYSE:ADCT) Price Target to $5.00
ADC Therapeutics (NYSE:ADCT – Get Rating) had its target price trimmed by Morgan Stanley from $7.00 to $5.00 in a research note published on Tuesday morning, Benzinga reports. The brokerage currently
Morgan Stanley Reaffirms Their Hold Rating on ADC Therapeutics (ADCT)
Morgan Stanley Lowers Price Target on ADC Therapeutics to $5 From $7, Maintains Equalweight Rating
08:50 AM EST, 01/24/2023 (MT Newswires) -- ADC Therapeutics SA (ADCT) has an average rating of outperform and price targets ranging from $5 to $25, according to analysts polled by Capital IQ. Price: 4
ADC Therapeutics Is Maintained at Equal-Weight by Morgan Stanley
ADC Therapeutics Is Maintained at Equal-Weight by Morgan Stanley
ADC Therapeutics Price Target Cut to $5.00/Share From $7.00 by Morgan Stanley
ADC Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 01/24/2023 5.76% Morgan Stanley $7 → $5 Maintains Equal-Weight 01/04/2023 323.06% HC Wainwright & Co. $21
Morgan Stanley Maintains Equal-Weight on ADC Therapeutics, Lowers Price Target to $5
Morgan Stanley analyst Matthew Harrison maintains ADC Therapeutics with a Equal-Weight and lowers the price target from $7 to $5.
Company Overview
More
ADC Therapeutics SA is a clinical-stage biotechnology company. It engages in the research and development and commercialization of targeted antibody drug conjugates for patients with hematological malignancies and solid tumors. Its clinical-stage product candidates include loncastuximab tesirine, camidanlumab tesirine, and ADCT-602. The company was founded by Christopher Martin on June 6, 2011 and is headquartered in Epalinges, Switzerland.
CEO： Mr. Christopher Martin
Market： NYSE
Listing Date： 05/15/2020
Paper Trade
More
Hot List
TradeSearchNews
SymbolLatest price%Chg
Loading...
Watchlist
No Stock Yet